Drug Trial Radar · NCT04506905
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Aug 28, 2020
Primary completion
Mar 22, 2022
Study completion Mar 22, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Aug 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens. Part 1 assessed multiple dose once-daily titration regimens of elpipodect in young adult participants with schizophrenia. Part 2 assessed multiple once-daily doses of elpipodect in elderly participants with schizophrenia and healthy elderly participants.
Conditions
- Schizophrenia
Interventions
ElpipodectDrug
MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
PlaceboDrug
Oral tablets of dose-matched placebo to MK-8189 according to randomization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 & 2: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 27 days
- Part 1 & 2: Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to approximately 27 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Woodland Research Northwest, LLC ( Site 0002)
Rogers, Arkansas
Parexel ( Site 0004)
Glendale, California
Collaborative NeuroScience Network ( Site 0008)
Long Beach, California
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida
RCA at Fort Lauderdale Behavioral Health Center ( Site 0006)
Oakland Park, Florida
Hassman Research Institute ( Site 0007)
Berlin, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.